Cullinan Therapeutics (CGEM) Enterprise Value (2021 - 2026)

Cullinan Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$628.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 18.41% year-over-year to -$628.7 million; the TTM figure through Mar 2026 stood at -$628.7 million (down 18.41% YoY), while the FY2025 annual figure was -$377.9 million, up 5.28% from the prior year.
• Enterprise Value for Q1 2026 stood at -$628.7 million, down from -$377.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$265.5 million in Q2 2025, with the low at -$1.1 billion in Q3 2024.
• The 5-year median for Enterprise Value is -$552.9 million (2022), against an average of -$585.0 million.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value slumped 160.21% in 2022, then jumped 59.93% in 2025.
• Cullinan Therapeutics' Enterprise Value stood at -$467.3 million in 2022, then grew by 0.09% to -$466.9 million in 2023, then gained by 14.54% to -$399.0 million in 2024, then gained by 5.28% to -$377.9 million in 2025, then tumbled by 66.37% to -$628.7 million in 2026.
• Business Quant data shows CGEM's Enterprise Value at -$628.7 million in Q1 2026, -$377.9 million in Q4 2025, and -$561.9 million in Q3 2025.